Merck and Daiichi Sankyo’s HER3-DXd ADC Patritumab Deruxtecan Passes Phase 3 Trial After FDA Rejection
Merck (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) announced that their antibody-drug conjugate (ADC) patritumab...
Drug
Kangfang Biotech Presents Groundbreaking mCRC Treatment Data at ESMO Congress
At the 2024 European Society for Medical Oncology (ESMO) Congress, Kangfang Biotech (HKG: 9926) debuted...
Kangfang Biotech’s Yivoxi Shows Promising Results in First-Line TNBC Treatment at ESMO Congress
At the 2024 European Society for Medical Oncology (ESMO) Congress, Kangfang Biotech (HKG: 9926) unveiled...
Kangfang Biotech’s Yivoxi Shows Promising Results in Treating R/M HNSCC at ESMO Congress
At the 2024 European Society for Medical Oncology (ESMO) Congress, Kangfang Biotech (HKG: 9926) unveiled...
Shanghai Pharmaceuticals’ Dual-Targeting CAR-T Therapy Advances with IND Re-Acceptance
Shanghai Pharmaceuticals Group Co., Ltd. (SHA: 601607)’s biotech subsidiary has announced that its investigational ‘CD19...
Novartis’ Cemiplimab Approved in China for Moderate-to-Severe Atopic Dermatitis
Novartis (SWX: NOVN, NYSE: NVS)’s Chinese arm has announced that it has received approval from...
Johnson & Johnson’s Tremfya Gains FDA Approval for Ulcerative Colitis Treatment
Johnson & Johnson (NYSE: JNJ) announced today that the US Food and Drug Administration (FDA)...
Roche’s Tecentriq Hybreza Becomes First Subcutaneous Anti-PD-(L)1 Immunotherapy in the US
Roche (SWX: ROG; OTCMKTS: RHHBY) , a leading Swiss pharmaceutical company, has secured US Food...
Lilly’s Once-Monthly Atopic Dermatitis Treatment Ebglyss Gets Green Light from FDA
Eli Lilly & Co. (NYSE: LLY) has announced that it has received market approval from...
Roche’s Ocrevus Zunovo Receives FDA Nod as First Twice-Yearly MS Treatment
Roche Group (SWX: ROG; OTCMKTS: RHHBY) , a Swiss pharmaceutical giant, has announced that the...
Ascentage Pharma’s Olverembatinib Shows Promise in SDH-Deficient GIST at ESMO Congress
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced the presentation of...
Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Receives Priority Review from China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Johnson & Johnson Submits Second NDA for Nipocalimab to Treat Generalized Myasthenia Gravis
Johnson & Johnson (NYSE: JNJ), a leading healthcare company based in the U.S., has reported...
Keymed Biosciences’ IL-4Rα mAb Stapokibart Receives NMPA Approval for Atopic Dermatitis Treatment
Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has announced that the...
Sanofi’s Dupixent Shows Promise in Phase III Trials for Rare Skin Disease and Chronic Hives
Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has announced positive results from...
Suzhou GenAssist Launches First-of-Its-Kind Base Editing Drug Trial for Duchenne Muscular Dystrophy
Suzhou GenAssist Therapeutic Co., Ltd, a biopharmaceutical company based in China, has announced the commencement...
Innovent Biologics’ Mazdutide Outperforms Dulaglutide in Phase III T2D Study at EASD Meeting
Innovent Biologics, Inc. (HKG: 1801), a biopharmaceutical company based in China, has presented significant findings...
Qilu Pharmaceutical’s Iruplinalkib Shows Promising Results in Phase II Study for ALK+ NSCLC
Qilu Pharmaceutical, a leading pharmaceutical company based in China, has presented updated results from the...
Nuance Pharma Completes Enrollment for Phase III COPD Trial of Ohtuvayre in China
Nuance Pharma, a China-based pharmaceutical company, has announced the completion of patient enrollment for the...
Innovent Biologics Presents Promising Phase I Data for IBI363 in Advanced NSCLC at WCLC
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has unveiled Phase...